Eli Lilly, Novo Nordisk, Sanofi Accused Of Artificially Raising Insulin Prices
Arkansas has accused Eli Lilly And Co (NYSE:LLY), Novo Nordisk A/S (NYSE:NVO), Sanofi SA (NASDAQ:SNY), and three of the largest pharmacy benefit managers (PBMs)…
Peering Into Novo Nordisk’s Recent Short Interest
Novo Nordisk's (NYSE:NVO) short percent of float has fallen 20.0% since its last report. The company recently reported that it has 2.07 million shares sold short, which is 0.12% of all regular shares that are available for trading.
Novo Nordisk’s Once-Weekly Insulin Icodec Shows Favorable Reduction In HbA1c In Type 2 Diabetes
Novo Nordisk A/S (NYSE:NVO) has announced topline results from Phase 3a ONWARDS 2 trial, 26-week efficacy and safety treat-to-target trial investigating…
Surprise Negative GDP Report Could Hurt Premarket Rally
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
House Passes Bill To Cap Out-of-Pocket Insulin Costs To No More Than $35/Month
The House of Representatives voted to approve legislation that would limit cost-sharing for insulin under private health insurance and Medicare.
Why Novo Nordisk Shares Are Trading Higher Today
The FDA has approved Novo Nordisk A/S’s (NYSE:NVO) 2.0 mg dose of Ozempic (once-weekly semaglutide subcutaneous injection), a glucagon-like peptide-1 (GLP-1)…
Aeterna Zentaris Says Enrollment In Growth Hormone Deficiency Trial To Continue Into 2023
Aeterna Zentaris Inc (NASDAQ: AEZS)